SCHEMBL4834053

SCHEMBL4834053

NC1=c2ccsc2=NCN1c1ccc(N)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.36
▸ ALDH1A1 P00352 4/20 0.36
▸ GAA P10253 4/20 0.36
▸ KDM4E B2RXH2 3/20 0.36
▸ GFER P55789 3/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ ADRA2C P18825 1/20 0.36
▸ PTK2B Q14289 1/20 0.36
▸ ESR2 Q92731 1/20 0.36
▸ HTT P42858 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ RECQL P46063 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4834301 0.84 PIP4K2A (0.31) —
SCHEMBL4825807 0.71 PKM (0.46) MAPTALDH1A1GAAKMT2APTK2B
SCHEMBL4826345 0.71 NPC1 (0.37) MAPTALDH1A1KDM4EKMT2AMEN1
SCHEMBL4829291 0.71 HDAC1 (0.45) MAPTALDH1A1GAAKDM4ENPC1
SCHEMBL4829145 0.71 NPC1 (0.48) MAPTKMT2AMEN1NPC1POLB
SCHEMBL4829073 0.71 NPY2R (0.48) KMT2AMEN1
SCHEMBL22495221 0.59 NPC1 (0.66) MAPTALDH1A1GAAKDM4EGFER
SCHEMBL10800977 0.57 INMT (0.40) MAPTALDH1A1GAAKDM4EGFER
SCHEMBL10881763 0.57 SIGMAR1 (0.46) MAPTALDH1A1GAAKDM4EGFER
SCHEMBL23347931 0.57 MAPT (0.77) MAPTALDH1A1GAAKDM4EGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK MAPT 2499/4885ALDH1A1 906/4885GAA 3329/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR MAPT 2424/4885ALDH1A1 1144/4885GAA 4356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback